Efficacy of ETB-F01, Heat-Killed Akkermansia muciniphila Strain EB-AMDK19, in Patients with Respiratory Symptoms: A Multicenter Clinical Trial
Nutrients · 2024
DOI: 10.3390/nu16234113 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Hyun Woo Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory and Critical Care, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical C…. Hauptthemen laut MEDLINE: Akkermansia, Probiotics. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory symptoms are prevalent in the general population, and they are associated with a decline in lung function and increased mortality. The gut–lung connection suggests intestinal dysbiosis may impact lung diseases, with Akkermansia muciniphila showing promise in regulating extraintestinal diseases. However, its application in patients with respiratory symptoms lacks clinical trial evidence. In this randomized, double-blind trial, ETB-F01, containing heat-killed A. muciniphila strain EB-AMDK19, was compared with a placebo in patients experiencing respiratory symptoms for 4 to 12 weeks. The primary outcome was improvement in Breathlessness, Cough, and Sputum Scale (BCSS) score over 12 weeks. Secondary outcomes included lung function, fractional exhaled nitric oxide (FeNO), modified Medical Research Council (mMRC) dyspnea scale, St. George’s Respiratory Questionnaire (SGRQ), and Visual Analog Scale (VAS) score. The primary analysis was performed in the per-protocol set, with a sensitivity analysis in the full analysis set. In the per-protocol population, 68 participants were randomly assigned to the ETB-F01 group and 65 to the placebo group. ETB-F01 had a superior efficacy over placebo in improving BCSS total scores (between-group difference = −0.8 (95% confidence interval, −1.4–−0.3), p-value = 0.004). Specifically, there was a significant reduction in BCSS breathlessness and cough domain scores with ETB-F01. While trends toward improvement in lung function were noted, statistical significance was not achieved. No significant differences were observed in FeNO and other symptom scores (mMRC, SGRQ, and VAS). In safety profile, ETB-F01 did not cause any serious adverse events. These results suggest that ETB-F01 is safe and effective for alleviating respiratory symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory and Critical Care, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, College of Medicine, Seoul National University, Seoul 07061, Re…
- Enterobiome Inc., Goyang-si 10326, Republic of Korea.
- Division of Pulmonology and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 21565, Republic of Korea.
- Department of Respiratory, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong 14353, Republic of Korea.
- Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Hospital, Seoul 07061, Republic of Korea.
ORCID-Profile: Cheon Woong Choi, Hye Sook Choi
Zitieren
APA
Lee, H. W., Lee, S. N., Seo, J. G., Koo, Y., Kang, S. Y., Choi, C. W., Park, S. Y., Lee, S. Y., Kim, S. R., Kim, J. H., & Choi, H. S. (2024). Efficacy of ETB-F01, Heat-Killed Akkermansia muciniphila Strain EB-AMDK19, in Patients with Respiratory Symptoms: A Multicenter Clinical Trial. Nutrients. https://doi.org/10.3390/nu16234113
Vancouver
Lee HW, Lee SN, Seo JG, Koo Y, Kang SY, Choi CW, et al. Efficacy of ETB-F01, Heat-Killed Akkermansia muciniphila Strain EB-AMDK19, in Patients with Respiratory Symptoms: A Multicenter Clinical Trial. Nutrients. 2024. doi:10.3390/nu16234113
BibTeX
@article{Lee2024,
author = {Lee, Hyun Woo and Lee, Sang-Nam and Seo, Jae-Gu and Koo, Yemo and Kang, Sung-Yoon and Choi, Cheon Woong and Park, So-Young and Lee, Suh-Young and Kim, Sung-Ryeol and Kim, Joo-Hee and Choi, Hye Sook},
title = {Efficacy of ETB-F01, Heat-Killed Akkermansia muciniphila Strain EB-AMDK19, in Patients with Respiratory Symptoms: A Multicenter Clinical Trial},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16234113}
}
EUVIMED